Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 16/20 | 0.55 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.47 |
| ▸ | UQCRB | P14927 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305838 | 0.89 | CCR9 (0.59) | CCR9GLO1HSD17B2UQCRB | |
| SCHEMBL10223796 | 0.87 | CCR9 (0.57) | CCR9GLO1HSD17B2UQCRB | |
| SCHEMBL10223672 | 0.85 | CCR9 (0.56) | CCR9HSD17B2UQCRB | |
| SCHEMBL10223694 | 0.84 | CCR9 (0.55) | CCR9HSD17B2UQCRB | |
| SCHEMBL10223757 | 0.84 | CCR9 (0.55) | CCR9HSD17B2UQCRB | |
| SCHEMBL10223682 | 0.83 | CCR9 (0.54) | CCR9HSD17B2UQCRB | |
| SCHEMBL306246 | 0.83 | CCR9 (0.54) | CCR9HSD17B2UQCRB | |
| SCHEMBL10223671 | 0.81 | CCR9 (0.52) | CCR9HSD17B2UQCRB | |
| SCHEMBL10223665 | 0.81 | CCR9 (0.56) | CCR9HSD17B2 | |
| SCHEMBL10223613 | 0.81 | CCR9 (0.57) | CCR9HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR9 2/4885GLO1 3863/4885HSD17B2 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.